Therapeutic Area Heritage

A leader in oncology and inflammation

At Amgen, we lead with action. Our world-class inflammation and oncology franchises have a laser-like focus on improving the lives of patients with life-threatening or chronic diseases.

Offering new biosimilars for the treatment of these diseases is one way we’re striving to improve patients’ lives. Because of their lower costs, biosimilars may help more patients get the medicines they need earlier in their disease progression.1 And that’s a good thing because biologic treatments for oncology and inflammation have changed the outlook for people with these diseases and everyone who cares for them.

Biologics in oncology

At Amgen, we are experts in the science of creating and manufacturing biologics and, now, biosimilar medicines for oncology patients.

Our biologics for cancer treatment include:

  • Immunotherapies
  • A biologic treatment used in the curative setting
  • Targeted therapies
    • These include monoclonal antibodies (mAbs), which revolutionized cancer treatment and continue to constitute an important treatment modality.2

Our oncology portfolio includes:


recently approved biosimilar medicine, and several more pending


innovative medicines in different phases of clinical development

Our history with oncology biologics includes not only the discovery, development, and production of these practice-changing medicines, but also our innovative delivery systems to help increase access and adoption.

Biologics for chronic inflammatory diseases

Biologics for chronic inflammatory diseases, such as rheumatoid arthritis, were a true advance. With their advent, the treatment plan was no longer about managing symptoms, but about putting the disease into remission by inhibiting specifically targeted biochemical pathways of inflammation.3

Amgen has been at the forefront of biologic medicines for inflammation for over 20 years. Now we have a pipeline that is rich in biosimilars that treat inflammation.4

References: 1. Boccia R, Jacobs I, Popovian R, de Lima Lopes G Jr. Can biosimilars help achieve the goals of US health care reform? Cancer Manag Res. 2017;9:197-205. 2. Shuptrine C, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol. 2012;22:3-13. 3. Keyser FD. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev. 2011;7:77-87. 4. Amgen. Amgen Pipeline. Accessed April 26, 2018.

Next: highly specialized knowledge

previous: Worldwide
Biologics leader